Co-Founder & COO at Differentiated Therapeutics - Boston, Massachusetts, United States
Differentiated Therapeutics (DXTX) has built the first end-to-end discovery engine for Targeted Protein Degradation (TPD) which drives the discovery and optimization of novel protein degraders designed to eliminate the genetically defined drivers of disease